article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

article thumbnail

Flora Growth Forms Flora Pharma Division, Launches Global Clinical Trials

Cannabis Law Report

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A Visit www.floragrowth.ca

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Survey: Three Of Four Military Veterans Would Consider Using Medical Cannabis

NORML

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

article thumbnail

Article: Intellectual Property Due Diligence in Psychedelics

Cannabis Law Report

For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. However, that does not mean that the path to patents is closed off.

article thumbnail

MAPS: Regulatory Publishing Specialist – Remote Position Regulatory Affairs · Any City, Any State, California

Cannabis Law Report

Reporting to the Regulatory Affairs Manager, the RPS supports functions related to tracking regulatory information and document styling and publishing in eCTD format for regulatory submissions. Position duties: Electronic document preparation and submission of electronic common technical document (eCTD) submissions to regulatory agencies.

article thumbnail

Global Regulatory Specialist – Melbourne – Medicinal Cannabis i-Pharm Consulting Australia Pty Ltd

Cannabis Law Report

Responsible for creation and maintenance of all regulatory documentation, including but not limited to, product packaging, labelling, inserts, working in conjunction with the marketing team for design, and assuring regulatory compliance across all territories. Support new product development and further clinical activities.